Analysis of Histopathological Heterogeneity of Urinary Bladder Cancer by Molecular Biological Technique.

1. c-erbB-2基因产物在人尿路移行细胞癌中被免疫电镜证实。与单克隆抗体的免疫反应仅限于细胞膜，呈线性模式。细胞间隙中的无定形沉积物也与针对细胞外表位的单克隆抗体免疫反应，表明c-erbB-2基因产物的一部分可能从癌细胞膜释放到细胞外间隙中.应用免疫组化和Western blot方法检测了c-erbB-2基因产物和表皮生长因子受体（EGF-R）在人膀胱癌中的表达。c-erbB-2基因产物在高级别肿瘤和高分期肿瘤中表达更频繁。而EGF-R的表达与这两个参数无关。这些结果提示c-erbB-2可能在控制癌细胞某些特异性反应中发挥与EGF-R不同的作用， ...更多信息 可作为恶性潜能的肿瘤标志物. cerbB-2基因产物在膀胱移行细胞癌石蜡包埋组织中表达。阳性率为26%。cerbB-2阳性者5年生存率明显低于cerbB-2阴性者（P<0.05）。从cerbB-2阳性标本中提取基因组DNA进行斑点杂交分析，结果显示cerbB-2基因在所有cerbB-2阳性的移行细胞癌患者中均未扩增，提示cerbB-2表达可作为判断移行细胞癌恶性潜能和预后的肿瘤标志物.用单克隆抗体MRK-16对人多药耐药基因mdr 1产物在正常肾脏的定位进行了研究。肾细胞癌和膀胱癌。mdr 1基因产物定位于细胞膜上，其表达率与组织学分级无关.癌症家族综合征同胞中的癌基因扩增。其中4例在50岁以前发生1 ~ 3例原发于胃肠道和/或泌尿生殖器官的癌。采用石蜡包埋法制备DNA进行检测. 3个同胞8例肿瘤中H-ras扩增1例，c-myc扩增6例，c-erbB-2扩增1例。在这个癌症家族中的癌基因扩增可能是遗传易感性的结果，并可能促进这些肿瘤的早期表现。少

1. The c-erbB-2 gene product was demonstrated immunoelectron microscopically in human transitional cell carcinomas of the urinary tract. The immune reaction with the monoclonal antibody was confined to cell membranes with a linear pattern. Amorphous deposits in the intercellular spaces were also immunoreactive with the monoclonal antibody directed to an extracellular epitope, suggesting that a part of the c-erbB-2 gene product may be released from the cancer cell membranes into the extracellular space.2. Expression of the c-erbB-2 gene product and the epidermal growth factor receptor (EGF-R) was investigated in human bladder cancer immunohistologically and by Western blot analysis. The c-erbB-2 gene product was more frequently expressed in high grade tumors and in high stage tumors. while the expression of EGF-R was independent of these two parameters. These results suggest that c-erbB-2 may play a different role from EGF-R to control some specific reaction of cancer cell, also it may … More be used as a tumor maker for the malignant potential.3. Expression of cerbB-2 gene product could be detected immunohistologically in paraffin-embeddedtissue specimen of transitional cell carcinoma. Positive rate of this staining was 26%. Five year survival rate of patients with cerbB-2 positive cancer was significantly shorter than that of patients with cerbB-2 negative cancer (p<0.05). Dot blot hybridization analysis using genomic DNA extracted from the cerbB-2 positive specimen demonstrated that the gene was not amplified in all patients with cerbB-2 positive cancer.These results suggest that cerbB-2 expression may be applicable as a tumor marker of malignant potential and prognostic factor of human transitional carcinoma.4. Localization of product of the human mdr1 standing for multidrug resistant gene was investigated with monoclonal antibody MRK-16 in normal kidney. Renal cell cancer and urinary bladder cancer. The mdr1 gene product was localized on cell membrane and there was no correlation between its expression rate and histological grading.5. Oncogene amplication in siblings of cancer family syndrome. In which 4 of 7 sidlings developed 1 to 3 primary carcinomas from the gastrointestinal and/or genitourinary organs before 50-year old. Was surveyed using DNA prepared from paraffin- embedded block. Of 8 tumors from 3 siblings H-ras was amplified in 1, c-myc in 6 and c-erbB-2 in 1. The oncogene amplification in this cancer family would be a consequence of hereditary predisposition and may have promote the early manifestation of these tumors. Less